Cutler Group’s Genetic Technologies Ltd. GENE Stock Holding History

Cutler Group’s Portfolio GENE Stock Details GENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,760	Closed	-$4K	–	6474
2020 Q4	$4K	Buy	+2,760	New	+$45.6K	﹤0.01%	3864

Other funds holding GENE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cetera Advisors Denver, Colorado $12.7B AUM 22.7% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cutler Group's GENE Position: Q4 2021 in Review

Cutler Group sold out of Genetic Technologies Ltd. (GENE) in Q4 2021, closing a stake of 20 shares.

Cutler Group first reported a position in GENE in Q3 2016 and held it in 21 quarters. The position peaked at $37K in Q1 2021. 13 funds tracked by Wall St. Rank hold GENE as of Q4 2021.

Cutler Group reported no remaining Genetic Technologies Ltd. position as of Q4 2021 after selling out during the quarter.
Cutler Group sold 20 Genetic Technologies Ltd. shares in Q4 2021.
Cutler Group first reported a position in Genetic Technologies Ltd. in Q3 2016 and held it in 21 quarters.
Cutler Group's Genetic Technologies Ltd. position peaked at $37K in Q1 2021.
13 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.